Attitudes about the treatment of obesity among healthcare providers involved in the care of obesity-related diseases: A survey across medical specialties in multiple European countries.

Autor: Rubino F; Diabetes and Nutritional Sciences King's College London London UK., Logue J; Lancaster Medical School Lancaster University Lancaster UK., Bøgelund M; Incentive Denmark Holte Denmark., Madsen ME; Incentive Denmark Holte Denmark., Cancino AP; Novo Nordisk North West Europe Pharmaceuticals A/S Copenhagen Denmark., Høy M; Novo Nordisk North West Europe Pharmaceuticals A/S Copenhagen Denmark., Panton UH; Novo Nordisk North West Europe Pharmaceuticals A/S Copenhagen Denmark.
Jazyk: angličtina
Zdroj: Obesity science & practice [Obes Sci Pract] 2021 May 21; Vol. 7 (6), pp. 659-668. Date of Electronic Publication: 2021 May 21 (Print Publication: 2021).
DOI: 10.1002/osp4.518
Abstrakt: Background and Rationale: Obesity is associated with the development and progression of many diseases. Understanding and management of obesity have become increasingly important; however, a knowledge gap remains between how healthcare providers (HCPs) consider weight-loss treatment and the importance of weight loss for improving obesity-related diseases.
Objective: The objective of this study was to investigate how HCPs assess obesity, how they interpret the relationship between obesity and 12 recognized co-morbidities of obesity (excluding diabetes), and their view about the value of various weight-loss therapies.
Methods: This was a cross-sectional, non-interventional, descriptive study. Participants were medical doctors (HCPs) from eight European countries.
Results: Eighty-nine percent of the 197 HCPs that completed the survey considered obesity a disease. For most of the 12 obesity-related diseases under consideration, a majority of HCPs agreed that weight loss could reverse the disease or prevent progression. Among HCPs who have recommended weight loss, lifestyle interventions were by far the most common recommendation. However, more than three out of four HCPs stated that they would be likely to prescribe anti-obesity medications if available and reimbursed.
Conclusion: Most HCPs in this survey consider obesity a disease that needs to be treated. However, the majority of HCPs appear to prefer recommending lifestyle changes, although it is well documented that weight loss obtained by lifestyle changes is difficult to maintain. These results underscore the need for improved education of HCPs involved in the treatment of obesity-related diseases.
Competing Interests: Francesco Rubino has received research grants from Ethicon and Medtronic, consulting fees from Ethicon, Medtronic, and Novo Nordisk, and he is part of the scientific advisory board of GI Dynamics and Keyron. Jennifer Logue has received research support from Slimming World and consulting fees from Novo Nordisk. Ulrik Haagen Panton, Ana‐Paula Cancino, and Maria Høy are employees at Novo Nordisk A/S. Mette Bøgelund and Maria Elmegaard Madsen are employees at Incentive Denmark ApS, which is a paid vendor of Novo Nordisk A/S. As employees of Novo Nordisk A/S, Ana‐Paula Cancino, Maria Høy, and Ulrik Haagen Panton are part of a Novo Nordisk A/S stock option program.
(© 2021 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: